Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewLDN 214117 is a potent and selective inhibitor of type I bone morphogenic protein (BMP) receptor ALK2 (IC50 = 24 nM). Shows preference for ALK1 and ALK2 over ALK3 and 164-fold selectivity for BMP6 inhibition (IC50 = 100 nM) over TGF-β1. Exhibits improved kinome selectivity over K 02288 (Cat.No. 4986) and low cytotoxicity.
Sold for research purposes under exclusive agreement from The Brigham and Women's Hospital Inc. US patent 14/776,302
M. Wt | 419.52 |
Formula | C25H29N3O3 |
Storage | Store at -20°C |
Purity | ≥98% (HPLC) |
CAS Number | 1627503-67-6 |
PubChem ID | 91754554 |
InChI Key | BHUXVRVMMYAXKN-UHFFFAOYSA-N |
Smiles | COC1=CC(C2=C(N=CC(C3=CC=C(N4CCNCC4)C=C3)=C2)C)=CC(OC)=C1OC |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
References are publications that support the biological activity of the product.
Mohedas et al (2014) Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants. J Med Chem. 57 7900 PMID: 25101911
Keywords: LDN 214117, LDN 214117 supplier, LDN214117, Inhibitors, Inhibits, ALK1, ALK2, BMP, Bone, morphogenic, protein, BMP6, TGF-, β1, TGF-b1, TGF-beta1, kinase, activin, receptor-like, kinases, and, Other, Activin, Receptors, 6152, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for LDN 214117.
There are currently no reviews for this product. Be the first to review LDN 214117 and earn rewards!
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Written by Kirsty E. Clarke, Victoria B. Christie, Andy Whiting and Stefan A. Przyborski, this review provides an overview of the use of small molecules in the control of stem cell growth and differentiation. Key signaling pathways are highlighted, and the regulation of ES cell self-renewal and somatic cell reprogramming is discussed. Compounds available from Tocris are listed.
Stem cells have potential as a source of cells and tissues for research and treatment of disease. This poster summarizes some key protocols demonstrating the use of small molecules across the stem cell workflow, from reprogramming, through self-renewal, storage and differentiation to verification. Advantages of using small molecules are also highlighted.